Biocon.
an Indian biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 65
What's happening
Earlier this month
One to three months ago
-
The European Medicines Agency is seeking a positive opinion regarding the market access for a Pertuzumab biosimilar.Some support3 reports
-
Pharma shares are gaining in demand, affecting major companies including Wockhardt, Biocon, Torrent Pharmaceuticals, and Laurus Labs.Some support1 report
-
Biocon founder supports Gowda's stance while Gowda serves as a minister in the Greater Bengaluru Authority.Some support1 report
-
Active Pine sells a stake in Biocon, Bank of Baroda divests shares via NSE IPO, and companies secure infrastructure contracts in Madhya Pradesh and Odisha.Some support2 reports1 development inside
-
Biocon secured a 10-year PDP allocation in Brazil.Some support5 reports
-
MSCI is reviewing Indian companies, leading to potential upgrades and removal risks for stocks like SBI Cards, Biocon, and Laurus Labs.Well supported9 reports4 developments inside
-
MSCI is reviewing Indian companies, with high probability for inclusion in the MSCI India Standard Index for several firms.Some support2 reports4 developments inside
-
Biocon achieved marketing approval in Japan, successfully strengthening its international portfolio.Some support1 report
-
Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.Some support1 report
-
Analyst reports are affecting company valuation targets for Biocon, involving Wells Fargo.Some support1 report
-
Proposed tariffs on generic drugs in the US market, announced on August 1st, affect Biocon, whose executive chairperson is Kiran Mazumdar-Shaw.Some support1 report
-
Power Grid Corporation of India, Biocon, and Aurobindo Pharma announced their quarterly financial results.Some support1 report
Gone quiet
No new reports in 90+ days-
Mylan plans to sell up to 92 million shares in Biocon.Some support1 report
-
Market pressures and external factors, including crude oil prices, are causing profit declines across several companies including Emami, Cipla, Biocon, Hyundai, and IDFC FIRST Bank.Some support1 report
-
Regulatory settlements and investment targets are driving biosimilar launches and facility expansion in the US.Some support1 report1 development inside
-
Biocon is showing signs of a bullish technical breakout from its consolidation phase, with trading targets set above Rs 400.Some support1 report
-
Biocon completed the acquisition of equity shares on June 30, 2026.Some support4 reports
-
City Union Bank, JSW Energy, and Biocon were recommended as top stocks to buy.Some support1 report
-
The event details the roles of major Indian pharmaceutical companies, government ministers, and policy bodies like NITI Aayog.Some support1 report3 developments inside
No events began in the chosen period. Widen it, or reset.
What's reaching Biocon
Events traced to Biocon, step by step, newest firstAround Biocon this week
News at the entities that move Biocon most-
FDA StructuralFDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.Moves Biocon
-
European Medicines Agency StructuralGlenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.Moves Biocon
-
MSCI StructuralXPeng maintained its highest AAA rating in MSCI's ESG assessment while S&P Global assessed its corporate sustainability.Moves Biocon
-
CNBC TransactionalCNBC and the International Air Transport Association are tracking trends related to disruptive passenger behavior.Moves Biocon
-
Abu Dhabi Investment Authority TransactionalAbu Dhabi Investment Authority and Aditya Birla Sun Life Mutual Fund invested in an Indian IPO anchor book.Moves Biocon
-
Amgen OperationalLaurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Moves Biocon
Connections
The 23 strongest of 65, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kiran Mazumdar-Shaw Structural
Kiran Mazumdar-Shaw is the founder and executive chairperson of Biocon.
-
FDA Structural
The FDA has granted supplemental drug approval, establishing a formal market access dependency for Biocon's product.
-
Amgen Operational
Amgen and Biocon are direct competitors in the Stelara biosimilar market.
-
Mylan Transactional
Mylan is currently planning the divestment of its 5.64% equity stake in Biocon.
-
BIS Structural
Biocon holds registrations and licenses issued by BIS, indicating a formal regulatory dependency.
-
CNBC Transactional
CNBC reported on a specific share sale event involving Biocon.
-
European Medicines Agency Structural
The European Medicines Agency is reviewing Biocon's biosimilar application for market access in Europe.
-
MSCI Structural
MSCI is evaluating Biocon as a candidate for inclusion or upgrade within its indices.
Show all 23 connections
-
Public Works Department Structural
Biocon's products are formally approved and listed by the Public Works Department.
-
Abu Dhabi Investment Authority Transactional
Abu Dhabi Investment Authority participated as an anchor investor in a share raise involving Biocon.
-
Wockhardt Mentioned together
Both companies are mentioned in the context of the broader pharmaceutical sector gaining market demand.
-
Container Corporation of India Mentioned together
The evidence suggests the companies are co-mentioned as successful entities within the market context.
-
City Union Bank Mentioned together
Both companies are grouped together in market recommendations as top stocks to buy.
-
JSW Energy Mentioned together
Market analysts recommend both companies as top stocks to buy, indicating they are viewed as successful peers in their respective markets.
-
Krishna Byre Gowda Mentioned together
Biocon's founder publicly supported Krishna Byre Gowda's stance.
-
Bengaluru Shared context
Biocon operates from its corporate headquarters located in the city of Bengaluru.
-
Wells Fargo Mentioned together
The relationship is characterized by the influence of market analyst reports on company valuation targets.
-
Supetar Mentioned together
Both companies are potential candidates for inclusion in a shared market index.
-
Donald Trump Shared context
Donald Trump's proposed tariffs on generic drugs are forecasted to influence Biocon's operating environment.
-
Singapore Shared context
Biocon was mentioned in the context of conferences held in Singapore.
-
Malaysia Shared context
Biocon conducts manufacturing operations within Malaysia.
-
Reuters Mentioned together
No relationship between Reuters and Biocon was observed in the provided evidence.
-
bank Mentioned together
No evidence was provided linking 'bank' and 'Biocon'.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
5 events- The European Medicines Agency is seeking a positive opinion regarding the market access for a Pertuzumab biosimilar.
- Pharma shares are gaining in demand, affecting major companies including Wockhardt, Biocon, Torrent Pharmaceuticals, and Laurus Labs.
- Biocon founder supports Gowda's stance while Gowda serves as a minister in the Greater Bengaluru Authority.
- Active Pine sells a stake in Biocon, Bank of Baroda divests shares via NSE IPO, and companies secure infrastructure contracts in Madhya Pradesh and Odisha.
- Biocon secured a 10-year PDP allocation in Brazil.
August 2026
5 events- Biocon achieved marketing approval in Japan, successfully strengthening its international portfolio.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- Analyst reports are affecting company valuation targets for Biocon, involving Wells Fargo.
- Proposed tariffs on generic drugs in the US market, announced on August 1st, affect Biocon, whose executive chairperson is Kiran Mazumdar-Shaw.
- Power Grid Corporation of India, Biocon, and Aurobindo Pharma announced their quarterly financial results.
Show 2 earlier months
July 2026
4 events- Mylan plans to sell up to 92 million shares in Biocon.
- Market pressures and external factors, including crude oil prices, are causing profit declines across several companies including Emami, Cipla, Biocon, Hyundai, and IDFC FIRST Bank.
- Regulatory settlements and investment targets are driving biosimilar launches and facility expansion in the US.
- Biocon is showing signs of a bullish technical breakout from its consolidation phase, with trading targets set above Rs 400.
June 2026
5 events- MSCI is reviewing Indian companies, leading to potential upgrades and removal risks for stocks like SBI Cards, Biocon, and Laurus Labs.
- MSCI is reviewing Indian companies, with high probability for inclusion in the MSCI India Standard Index for several firms.
- Biocon completed the acquisition of equity shares on June 30, 2026.
- City Union Bank, JSW Energy, and Biocon were recommended as top stocks to buy.
- The event details the roles of major Indian pharmaceutical companies, government ministers, and policy bodies like NITI Aayog.